N4 Pharma PLC
LSE:N4P

Watchlist Manager
N4 Pharma PLC Logo
N4 Pharma PLC
LSE:N4P
Watchlist
Price: 0.425 GBX Market Closed
Market Cap: 3.5m GBX
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

N4P doesn't have a meaningful market cap.

The Relative Value of one N4P stock under the Base Case scenario is 0.009 GBX. Compared to the current market price of 0.425 GBX, N4 Pharma PLC is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

N4P Relative Value
Base Case
0.009 GBX
Overvaluation 98%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

484.5
P/S
P/S
Price to Sales
484.5
vs History
28
vs Industry
1
Median 3Y
484.6
Median 5Y
0
Industry
2.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-13.8
Industry
22.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-14.7
Industry
17.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-14.7
Industry
23.9
More Details
5.5
P/B
P/B
Price to Book Value
5.5
vs History
82
vs Industry
48
Median 3Y
6.3
Median 5Y
9.2
Industry
2.3
More Details
398.8
EV/S
EV/S
Enterprise Value to Sales
398.8
vs History
28
vs Industry
2
Median 3Y
395.3
Median 5Y
0
Industry
2.9
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-10.3
Industry
13.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-10.3
Industry
16.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-13.6
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-13.6
Industry
17.8
More Details
24.1
EV/IC
EV/IC
Enterprise Value to IC
24.1
vs History
73
vs Industry
14
Median 3Y
27.5
Median 5Y
30.9
Industry
2
More Details

Multiples Across Competitors

N4P Competitors Multiples
N4 Pharma PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
N4 Pharma PLC
LSE:N4P
3.5m GBP 484.5 -3.3 -2.4 -2.4
US
Eli Lilly and Co
NYSE:LLY
695.1B USD 13.1 50.4 29.8 32.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
425.3B USD 4.7 18.8 14.3 18.8
CH
Roche Holding AG
SIX:ROG
208.9B CHF 3.5 25.2 9.5 11.1
UK
AstraZeneca PLC
LSE:AZN
184.2B GBP 4.4 30 113.8 170.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 14.3 10.4 11.6
CH
Novartis AG
SIX:NOVN
197.4B CHF 4.5 18 10.8 14.4
US
Merck & Co Inc
NYSE:MRK
211.5B USD 3.3 12.9 8.3 9.9
IE
Endo International PLC
LSE:0Y5F
195.2B USD 84.2 -66.8 310 777.3
US
Pfizer Inc
NYSE:PFE
142.5B USD 2.2 13.3 7.5 10.3
P/E Multiple
Earnings Growth PEG
UK
N4 Pharma PLC
LSE:N4P
Average P/E: 22.9
Negative Multiple: -3.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
50.4
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.8
28%
0.7
CH
Roche Holding AG
SIX:ROG
25.2
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
37%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
10%
1.4
CH
Novartis AG
SIX:NOVN
18
18%
1
US
Merck & Co Inc
NYSE:MRK
12.9
16%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -66.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.3
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
N4 Pharma PLC
LSE:N4P
Average EV/EBITDA: 436.1
Negative Multiple: -2.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.8
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.3
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.8
10%
11.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
13%
0.8
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.3
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
310
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
N4 Pharma PLC
LSE:N4P
Average EV/EBIT: 1 875.8
Negative Multiple: -2.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.3
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.8
14%
1.3
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
170.1
23%
7.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
14%
0.8
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
777.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
9%
1.1

See Also

Summary
N4P intrinsic value, competitors valuation, and company profile.
DCF Valuation
N4P stock valuation using Discount Cash Flow valuation method.
Relative Valuation
N4P stock valuation using valuation multiples.
Wall Street Estimates
N4P price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
N4P stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 278,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.